查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085357

兒童失神性癲癇治療市場：依療法、藥物類別、最終用戶和分銷管道分類－2026-2032年全球市場預測

Childhood Absence Epilepsy Treatment Market by Treatment Type, Drug Class, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，兒童失神性癲癇治療市場將成長至 4.6047 億美元，複合年成長率為 7.77%。

主要市場統計數據
基準年 2025 2.7262億美元
預計年份：2026年 2.9622億美元
預測年份 2032 4.6047億美元
複合年成長率 (%) 7.77%

兒童失神性癲癇（CAE）是兒童整體癲癇症候群，其特徵為短暫的失神發作、意識改變以及整體的3 Hz棘慢波腦電圖（EEG）模式。此病最常發生於4至10歲之間，儘管失神發作持續時間短，但未經治療的失神發作可能具有重要的臨床意義，因為它們會影響課堂學習、注意力、安全和生活品質。

兒童失神性癲癇的治療以實證抗癲癇藥物為中心，其中乙琥胺被廣泛認為是治療典型失神發作（當失神發作是唯一發作類型時）的一線藥物。丙戊酸在伴隨整體強直-陣攣性發作時仍然重要，而拉莫三嗪儘管在兒童對比研究中顯示出較低的無發作率，但在某些情況下仍會被使用。早期診斷、兒童神經科就診的便利性、對長期安全性的期望、學名藥的可及性、學校對癲癇的認知提高以及腦電圖（EEG）等數位化工作流程的日益普及等因素，都推動了對更高品質醫療服務的需求。

治療環境的變革性變化

兒童期癲癇（CAE）治療中最顯著的變化是從單純的症狀識別轉向更快速、基於實證醫學的診斷和個人化治療方案的選擇。在診療過程中進行過度換氣誘發試驗、採用標準化的腦電圖（EEG）解讀方法以及系統地記錄癲癇發作史，使臨床醫生能夠縮短從課堂上首次觀察到癲癇發作到開始治療之間的時間。

人工智慧（AI）的累積影響

人工智慧 (AI) 正透過最佳化腦電圖 (EEG) 工作流程、自動檢測棘慢波模式、遠端監測和臨床決策支持，開始影響兒童癲癇 (CAE) 的治療。 AI 驅動的 EEG 閱片有助於優先處理疑似顯示癲癇樣活動的檢查，確保放射科醫生之間的診斷一致性，並緩解兒童神經生理基礎設施有限地區的診斷瓶頸。

主要區域洞察：亞太地區、北美地區、拉丁美洲地區、歐洲地區、中東和非洲地區

亞太地區為兒童失神性癲癇治療領域的快速成長提供了廣闊前景。這主要得益於大規模的兒童人口、不斷擴大的神經科服務以及東協市場（包括中國、印度、日本、韓國、澳洲和東協其他成員國）診斷率的提高。然而，大城市和農村地區三級醫療中心之間的就醫機會仍然存在差距，因此遠距神經病學、非專利抗癲癇藥物、學校宣傳教育計畫以及臨床醫生培訓等因素成為推動該領域發展的關鍵驅動力。

關鍵區域洞察：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

在東協市場，由於公共醫療體系的擴張和私立醫院引進先進的腦電圖（EEG）平台，兒童神經病學的重要性日益凸顯。然而，成本效益、農村地區的醫療服務可及性以及專科醫生的短缺仍然是主要阻礙因素。海灣合作理事會（GCC）地區透過對專科醫院、數位醫療基礎設施和轉診網路的投資，在眾多地區中脫穎而出，加快了主要城市兒科神經病學服務的普及，並促進了兒童動脈粥樣硬化（CAE）診斷和治療路徑的標準化。

對主要 CAE 治療市場關鍵國家的洞察

美國憑藉其龐大的兒童癲癇中心、完善的學校醫療體係以及廣泛應用的處方箋實踐，仍然是兒童失神性癲癇治療領域的領先國家。然而，加拿大則更注重公共資助的醫療服務體系、專科轉診系統以及跨省醫療資源的公平取得。墨西哥和巴西是拉丁美洲的關鍵市場，提高診斷能力、減少專科醫生診療機會的差異以及確保乙琥胺、丙戊酸和拉莫三嗪的穩定供應是其首要任務。

為行業領導者提供的實用建議

產業領導者應優先考慮以實證醫學為基礎的治療方案，支持早期發現、透過腦電圖（EEG）快速確診以及一線使用合適的抗癲癇藥物。與小兒科、學校和看護者進行教育合作，可以減少診斷延誤，提高用​​藥依從性，特別是因為兒童失神性癲癇（CAE）的發作常常被誤認為是注意力不集中或白日夢。

調查方法

本執行摘要基於對兒童癲癇領域同行評審文獻、臨床指南指南、監管文件、公共衛生資訊來源以及權威癲癇組織提供的二手研究和證據的融合。它重點關注檢驗的臨床事實，包括該症候群的定義、診斷標準、治療方案的比較證據、藥物安全性考慮以及已知的獲取障礙。

結論

兒童失神性癲癇的治療正朝著早期診斷、更規範的一線治療方案以及更廣泛地應用數位化工具來輔助腦電圖（EEG）解讀和長期照護的方向發展。最大的機會在於改善兒童神經科的就醫途徑，提高家長和學校的認知，並確保有效抗癲癇藥物的穩定供應。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：兒童失神性癲癇治療市場：依治療類型分類

  • 抗癲癇藥物
  • 飲食療法
    • 生酮飲食
    • 改良的阿特金森療法
  • 神經刺激療法
    • 深部腦部刺激療法
    • 迷走神經刺激療法

第8章：兒童失神性癲癇治療市場：依藥物類別分類

  • 乙琥胺
  • 拉莫三嗪
  • 左乙拉西坦
  • 丙戊酸

第9章：兒童失神性癲癇治療市場：依最終用戶分類

  • 居家醫療
    • 看護者管理
    • 居家護理
  • 醫院
    • 住院治療
    • 門診
  • 專科診所
    • 癲癇監測單元
    • 兒童神經學中心

第10章：兒童失神性癲癇治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章：兒童失神性癲癇治療市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章：兒童失神性癲癇治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：兒童失神性癲癇治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • AbbVie Inc.
  • Aurobindo Pharma Ltd.
  • Bausch Health Companies Inc.
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • GlaxoSmithKline plc
  • Jazz Pharmaceuticals plc
  • Johnson & Johnson
  • Lundbeck A/S
  • Marinus Pharmaceuticals Inc.
  • Neurelis Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • SK Biopharmaceuticals Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Supernus Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
  • Viatris Inc.
Product Code: MRR-433AB1DC2923

The Childhood Absence Epilepsy Treatment Market is projected to grow by USD 460.47 million at a CAGR of 7.77% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 272.62 million
Estimated Year [2026] USD 296.22 million
Forecast Year [2032] USD 460.47 million
CAGR (%) 7.77%

Childhood absence epilepsy (CAE) is a common pediatric generalized epilepsy syndrome characterized by brief staring spells, impaired awareness, and a classic generalized 3-Hz spike-and-wave electroencephalography pattern. The condition most often begins between ages 4 and 10 and is clinically important because untreated absence seizures can disrupt classroom learning, attention, safety, and quality of life despite their short duration.

The childhood absence epilepsy treatment landscape is anchored by evidence-based antiseizure medicines, with ethosuximide widely recognized as first-line therapy for typical absence seizures when absence seizures are the only seizure type. Valproate remains important when generalized tonic-clonic seizures coexist, while lamotrigine is used in selected cases despite lower seizure-free response in comparative pediatric evidence. Demand for improved care is shaped by early diagnosis, pediatric neurology access, long-term safety expectations, generic drug availability, school-based awareness, and the rising role of EEG-enabled digital workflows.

Transformative Shifts in the Treatment Landscape

The most important shift in CAE treatment is the move from symptom recognition alone to faster, evidence-based diagnostic confirmation and individualized therapy selection. Hyperventilation provocation during examination, standardized EEG interpretation, and structured seizure-history capture are helping clinicians reduce delays between first classroom-observed episodes and treatment initiation.

Therapeutic decision-making is also becoming more precise. Randomized comparative evidence has reinforced ethosuximide as a preferred first-line option for CAE because it demonstrated strong seizure-control performance with fewer attentional adverse effects than valproate in children with absence-only disease. At the same time, clinicians are paying closer attention to comorbid attention, learning, mood, sleep, and family adherence factors, making the treatment model more multidisciplinary than drug-centered.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence CAE treatment through EEG workflow optimization, automated spike-and-wave pattern detection, remote monitoring, and clinical decision support. AI-assisted EEG review can help prioritize studies with suspected epileptiform activity, support consistency across readers, and reduce diagnostic bottlenecks in regions with limited pediatric neurophysiology capacity.

The cumulative impact is expected to be strongest when AI is embedded into validated clinical pathways rather than used as a stand-alone diagnostic authority. For CAE, the highest-value applications include triaging EEG backlogs, identifying treatment-response signals in longitudinal data, supporting adherence interventions, and improving clinical study enrollment by detecting eligible pediatric patients with consistent seizure phenotypes. Privacy, pediatric data governance, algorithmic bias, clinician oversight, and prospective validation remain central requirements for responsible adoption.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Asia-Pacific is a high-growth environment for childhood absence epilepsy treatment because large pediatric populations, expanding neurology services, and wider EEG availability are increasing diagnosis rates in China, India, Japan, South Korea, Australia, and ASEAN markets. However, access remains uneven between tertiary urban centers and rural communities, making tele-neurology, generic antiseizure medicines, school awareness programs, and clinician training important growth enablers.

North America benefits from established pediatric epilepsy centers, broad guideline adoption, and high use of EEG-based confirmation, with the United States and Canada emphasizing evidence-based drug selection, school-based seizure action plans, adherence support, and payer scrutiny of specialty care pathways. Latin America shows rising demand in Brazil and Mexico, where access to pediatric neurologists, public-sector diagnostic capacity, and consistent medicine supply are decisive factors. Europe is shaped by national health systems, pediatric neurology networks, and European Union pharmacovigilance standards, supporting structured prescribing and long-term safety monitoring. The Middle East is investing in tertiary epilepsy services across Gulf markets, digital health infrastructure, and specialist referral networks, while Africa faces the largest diagnosis and treatment gaps, making affordable medicines, EEG access, epilepsy workforce development, and stigma reduction central to improving outcomes.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN markets are increasingly relevant as public health systems expand child neurology capacity and private hospitals adopt modern EEG platforms, yet affordability, rural access, and specialist availability remain key constraints. The GCC is differentiated by investment in specialized hospitals, digital health infrastructure, and referral networks, supporting faster access to pediatric neurology in major cities and improving the ability to standardize CAE diagnosis and treatment pathways.

The European Union combines strong regulatory oversight, pharmacovigilance, and cross-country clinical practice alignment, supporting consistent use of established antiseizure medicines and pediatric safety monitoring. BRICS countries represent a large-volume care opportunity because China, India, Brazil, Russia, and South Africa combine sizable pediatric populations with rising healthcare investment, though access varies widely by region, income level, and availability of EEG diagnostics. G7 countries lead in clinical evidence generation, reimbursement oversight, pediatric neurology capacity, and digital health adoption. NATO markets overlap heavily with North American and European systems, where healthcare resilience, supply-chain security, and pediatric medicine availability are increasingly strategic priorities for continuity of epilepsy care.

Key Country Insights Across Major CAE Treatment Markets

The United States remains a leading environment for childhood absence epilepsy treatment because of its pediatric epilepsy centers, school health infrastructure, and strong use of evidence-based prescribing, while Canada emphasizes publicly funded care pathways, specialist referral systems, and equitable access across provinces. Mexico and Brazil are important Latin American markets where improving diagnostic capacity, reducing specialist access gaps, and reliable availability of ethosuximide, valproate, and lamotrigine are central priorities.

In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from structured specialist referral systems, national health coverage models, and established pharmacovigilance practices, although appointment wait times can affect speed of diagnosis. Russia has a large pediatric population and continued demand for accessible antiseizure therapy supported by practical EEG availability. China and India are major growth countries due to population scale, rising EEG access, and expanding pediatric neurology services, while Japan, South Korea, and Australia combine advanced diagnostics with high expectations for treatment safety, adherence monitoring, school reintegration, and long-term developmental outcomes.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence-aligned treatment pathways that support early recognition, rapid EEG confirmation, and first-line use of appropriate antiseizure medicines. Educational partnerships with pediatricians, schools, and caregivers can reduce diagnostic delays and improve adherence, especially because CAE seizures are often mistaken for inattentiveness or daydreaming.

Pharmaceutical, digital health, and provider organizations should focus on pediatric-friendly formulations, consistent generic supply, real-world safety monitoring, and validated AI tools that improve EEG access without compromising clinical governance. Regional strategies should be tailored to local barriers: affordability and workforce development in emerging markets, payer evidence and outcomes documentation in mature systems, and integrated care models across all settings. Leaders should also strengthen caregiver support, school-based seizure action planning, and transition frameworks for children who require ongoing epilepsy care.

Research Methodology

This executive summary is built from secondary research and evidence synthesis across peer-reviewed pediatric epilepsy literature, clinical guideline positions, regulatory references, public health sources, and recognized epilepsy organizations. Emphasis was placed on verified clinical facts, including syndrome definition, diagnostic standards, comparative treatment evidence, medication safety considerations, and known access barriers.

The analysis applies a market-intelligence framework that evaluates disease burden, treatment standards, regional healthcare infrastructure, reimbursement dynamics, digital health adoption, workforce capacity, and medicine availability. Insights were cross-checked for consistency and presented in language relevant to childhood absence epilepsy treatment, pediatric epilepsy care, antiseizure medicine use, EEG diagnostics, and AI-enabled neurology workflows.

Conclusion

Childhood absence epilepsy treatment is moving toward earlier diagnosis, more consistent first-line therapy, and broader integration of digital tools that support EEG interpretation and longitudinal care. The strongest opportunities lie in improving access to pediatric neurology, strengthening caregiver and school awareness, and ensuring reliable supply of proven antiseizure medicines.

As AI and tele-neurology mature, their value will depend on clinical validation, equitable deployment, pediatric data protection, and integration with established pediatric epilepsy standards. Stakeholders that combine evidence-based therapy, accessible diagnostics, and patient-centered support will be best positioned to improve outcomes in the global CAE treatment environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Childhood Absence Epilepsy Treatment Market, by Treatment Type

  • 7.1. Anti-Seizure Medication
  • 7.2. Dietary Therapy
    • 7.2.1. Ketogenic Diet
    • 7.2.2. Modified Atkinson Regimen
  • 7.3. Neurostimulation
    • 7.3.1. Deep Brain Stimulation
    • 7.3.2. Vagus Nerve Stimulation

8. Childhood Absence Epilepsy Treatment Market, by Drug Class

  • 8.1. Ethosuximide
  • 8.2. Lamotrigine
  • 8.3. Levetiracetam
  • 8.4. Valproate

9. Childhood Absence Epilepsy Treatment Market, by End User

  • 9.1. Home Care Settings
    • 9.1.1. Caregiver Managed
    • 9.1.2. Home Nursing
  • 9.2. Hospitals
    • 9.2.1. Inpatient
    • 9.2.2. Outpatient
  • 9.3. Specialty Clinics
    • 9.3.1. Epilepsy Monitoring Units
    • 9.3.2. Pediatric Neurology Centers

10. Childhood Absence Epilepsy Treatment Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies

11. Childhood Absence Epilepsy Treatment Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Childhood Absence Epilepsy Treatment Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Childhood Absence Epilepsy Treatment Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Concentration Analysis, 2025
    • 14.1.1. Concentration Ratio (CR)
    • 14.1.2. Herfindahl Hirschman Index (HHI)
  • 14.2. Recent Developments & Impact Analysis, 2025
  • 14.3. Product Portfolio Analysis, 2025
  • 14.4. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. AbbVie Inc.
  • 15.2. Aurobindo Pharma Ltd.
  • 15.3. Bausch Health Companies Inc.
  • 15.4. Cipla Ltd.
  • 15.5. Dr. Reddy's Laboratories Ltd.
  • 15.6. Eisai Co., Ltd.
  • 15.7. GlaxoSmithKline plc
  • 15.8. Jazz Pharmaceuticals plc
  • 15.9. Johnson & Johnson
  • 15.10. Lundbeck A/S
  • 15.11. Marinus Pharmaceuticals Inc.
  • 15.12. Neurelis Inc.
  • 15.13. Novartis AG
  • 15.14. Pfizer Inc.
  • 15.15. Sanofi S.A.
  • 15.16. SK Biopharmaceuticals Co., Ltd.
  • 15.17. Sun Pharmaceutical Industries Ltd.
  • 15.18. Supernus Pharmaceuticals Inc.
  • 15.19. Takeda Pharmaceutical Company Limited
  • 15.20. Teva Pharmaceutical Industries Ltd.
  • 15.21. UCB S.A.
  • 15.22. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTI-SEIZURE MEDICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-SEIZURE MEDICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-SEIZURE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DIETARY THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DIETARY THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DIETARY THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL KETOGENIC DIET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL KETOGENIC DIET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL KETOGENIC DIET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MODIFIED ATKINSON REGIMEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MODIFIED ATKINSON REGIMEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MODIFIED ATKINSON REGIMEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEUROSTIMULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEUROSTIMULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEUROSTIMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DEEP BRAIN STIMULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DEEP BRAIN STIMULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DEEP BRAIN STIMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VAGUS NERVE STIMULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VAGUS NERVE STIMULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VAGUS NERVE STIMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ETHOSUXIMIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ETHOSUXIMIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ETHOSUXIMIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LAMOTRIGINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LAMOTRIGINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LAMOTRIGINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LEVETIRACETAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LEVETIRACETAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LEVETIRACETAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VALPROATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VALPROATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VALPROATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CAREGIVER MANAGED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CAREGIVER MANAGED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CAREGIVER MANAGED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HOME NURSING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HOME NURSING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HOME NURSING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INPATIENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INPATIENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INPATIENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL OUTPATIENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL OUTPATIENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL OUTPATIENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL EPILEPSY MONITORING UNITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL EPILEPSY MONITORING UNITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL EPILEPSY MONITORING UNITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PEDIATRIC NEUROLOGY CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PEDIATRIC NEUROLOGY CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PEDIATRIC NEUROLOGY CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. GCC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 148. GCC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. GCC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. GCC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2032 (USD MILLION)
  • TABLE 151. GCC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 152. GCC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. GCC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 154. GCC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 155. GCC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 156. GCC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. G7 CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 178. G7 CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. G7 CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 180. G7 CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2032 (USD MILLION)
  • TABLE 181. G7 CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 182. G7 CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. G7 CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 184. G7 CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 185. G7 CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 186. G7 CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. NATO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. NATO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. NATO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. NATO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2032 (USD MILLION)
  • TABLE 191. NATO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 192. NATO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. NATO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 194. NATO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 195. NATO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 196. NATO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 211. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2032 (USD MILLION)
  • TABLE 212. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 215. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 216. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 217. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 219. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 221. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2032 (USD MILLION)
  • TABLE 222. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 223. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 225. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 226. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 227. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 229. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 231. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2032 (USD MILLION)
  • TABLE 232. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 233. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 235. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 236. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 237. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 249. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2032 (USD MILLION)
  • TABLE 252. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 253. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 255. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 256. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 257. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 259. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 261. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2032 (USD MILLION)
  • TABLE 262. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 263. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 265. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 266. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 267. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 268. RUSSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. RUSSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. RUSSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 271. RUSSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2032 (USD MILLION)
  • TABLE 272. RUSSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 273. RUSSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. RUSSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 275. RUSSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 276. RUSSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 277. RUSSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 278. ITALY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 279. ITALY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. ITALY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 281. ITALY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2032 (USD MILLION)
  • TABLE 282. ITALY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 283. ITALY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 284. ITALY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 285. ITALY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 286. ITALY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 287. ITALY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 288. SPAIN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 289. SPAIN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. SPAIN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 291. SPAIN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2032 (USD MILLION)
  • TABLE 292. SPAIN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 293. SPAIN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. SPAIN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 295. SPAIN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 296. SPAIN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 297. SPAIN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 308. INDIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 309. INDIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. INDIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 311. INDIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2032 (USD MILLION)
  • TABLE 312. INDIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 313. INDIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 314. INDIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 315. INDIA CHILDHOOD ABSENCE EPILEPSY TREATMENT M